Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
出版年份 2020 全文链接
标题
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e001302
出版商
BMJ
发表日期
2020-12-24
DOI
10.1136/jitc-2020-001302
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
- (2020) Michael A. Postow et al. CLINICAL CANCER RESEARCH
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
- (2020) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti-PD-1-resistant model of non-small-cell lung cancer
- (2020) Dawei Chen et al. Cancer Immunology Research
- A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial
- (2019) Jean-Louis Pujol et al. Journal of Thoracic Oncology
- Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy
- (2019) Suzanne Ostrand-Rosenberg et al. Frontiers in Oncology
- Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer
- (2019) James W. Welsh et al. Journal of Thoracic Oncology
- Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
- (2019) Neal E. Ready et al. Journal of Thoracic Oncology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
- (2019) Hyun Cheol Chung et al. Journal of Thoracic Oncology
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 expression in neuroendocrine tumors of the lung
- (2017) Kenjiro Tsuruoka et al. LUNG CANCER
- Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial
- (2017) Ben J. Slotman et al. LUNG CANCER
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Consolidative thoracic radiotherapy for extensive stage small cell lung cancer
- (2017) Xiaoli Zhang et al. Oncotarget
- Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor
- (2017) Kentaro Inamura et al. Cancer Medicine
- Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
- (2016) Julie George et al. CLINICAL CANCER RESEARCH
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer
- (2015) Parvin Forghani et al. BREAST CANCER RESEARCH AND TREATMENT
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
- (2014) C. Tang et al. Cancer Immunology Research
- Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
- (2014) liufu deng et al. OncoImmunology
- Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer
- (2013) Taofeek K. Owonikoko et al. CANCER
- A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
- (2012) Taofeek K. Owonikoko et al. Journal of Thoracic Oncology
- Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage
- (2008) K. Koyama et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started